Ferrero 2010.
Methods | Randomised controlled trial, single centre | |
Participants | 144 women Inclusion criteria: no specific details but included women who had had moderate or severe OHSS or who had been at risk of OHSS during their first IVF/ICSI cycle with a mid‐luteal long agonist protocol Exclusion criteria: no details Setting and timing: Italy; no details of timing Baseline characteristics: not stated |
|
Interventions |
Antagonist ‐ cetrorelix 0.25 mg/day starting on day 3 of the menstrual cycle Agonist ‐ triptorelin 0.1 mg/day starting on day 21 of the menstrual cycle Ovarian stimulation was achieved with rFSH initiated on day 3 of the cycle at a maximum dose of 150 IU and dose adjusted depending on ovarian response Luteal phase support ‐ with micronised progesterone vaginal gel (no other details) Follow‐up ‐ followed‐up to live birth |
|
Outcomes | Live birth, clinical pregnancy, cancellation rate, oocytes retrieved | |
Notes | As no denominators for groups are given, the data cannot be included in a meta‐analysis | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | No details |
Allocation concealment (selection bias) | Unclear risk | No details |
Blinding (performance bias and detection bias) All outcomes | Unclear risk | Open label but blinding unlikely to effect fertility outcome. No details of blinding of outcome assessors |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Although the abstract states that there were 144 women randomised, there are no other denominators to indicate how many women were allocated to each group. No details on withdrawals or losses to follow‐up |
Selective reporting (reporting bias) | Unclear risk | Conference abstract only. Outcomes are not pre‐specified. OHSS not reported |
Other bias | Unclear risk | Conference abstract only. Groups were reported as being similar at baseline |